

NEUROBLASTOMA UK

England & Wales · Charity number 326385

Details

Other names	THE NEUROBLASTOMA SOCIETY
Status	Registered
Legal form	Other
Registered	1983-07-20
Register	View on the Charity Commission register

Contact

Address	Canopi Unit A Arc House 82 Tanner Street London SE1 3GN
Phone	0203 096 7890
Email	secretary@neuroblastoma.org.uk
Website	www.neuroblastoma.org.uk

Activities

Objects: THE RELIEF OF CHILDREN SUFFERING FROM NEUROBLASTOMA

Activities: Neuroblastoma UK raises money to fund scientific research into the causes of neuroblastoma (a cancer affecting mainly young children) and improved treatments. It also provides support and advice to parents and others affected by the disease.

Classification

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People

Geography

- **Area of benefit:** ENGLAND, WALES, SCOTLAND AND NORTHERN IRELAND
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£303,350	£1,185,345	-	-
2023-12-31	£664,959	£151,102	£586,048	3
2022-12-31	£268,417	£818,780	-	-
2021-12-31	£417,323	£121,683	-	-
2020-12-31	£340,908	£440,816	-	-

Trustees

Name	Role	Appointed
Clair Cliff		2025-03-07
DR Katherine Wheeler		2013-02-01
Dr MARTIN ELLIOTT		2025-03-07
Dr Rebecca Louise Van Goethem		2026-06-01
Faye Watts		2017-04-27
Janet Elizabeth Davies		2026-06-01
Jonathan Anderson		2026-06-01
MALCOLM HUGH DEAN		2018-10-02
PROFESSOR DEBORAH ANNE TWEDDLE		2010-10-21
Ruby Charlotte Dickens		2018-10-02
STEPHEN MICHAEL SMITH		2004-04-13
Victoria Eadington		2023-09-10
Zara Aitchison		2019-09-17

Accounts



NEUROBLASTOMA UK

Charity Commission reference number
326385

REPORTS AND FINANCIAL STATEMENTS

For the year ended 31 December, 2024

NEUROBLASTOMA UK

REPORT AND FINANCIAL STATEMENTS

For the year ended 31 December, 2023

CONTENTS

	Page
Trustees' annual report	2-5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance sheet	8
Notes to the financial statements	9-12

TRUSTEES' ANNUAL REPORT for the year to 31 December, 2024

The Trustees present their report with the financial statements of the Charity for the year ended 31 December, 2024. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015). As a charity registered in England and Wales, the Charity also reports in accordance with the Charity Commission for England and Wales' guidance on public benefit and the Charities Act 2015.

Section A Reference and administrative details

Charity Name	NEUROBLASTOMA UK
Registered Charity Number	326385
Registered Address	Canopi, 82 Tanner Street, London SE1 3GN

Trustees who manage the Charity:

Zara Aitchison (Co-Chair)
Andy Pearson (Co-Chair) – resigned 7 November, 2024
Tori Eadington (Secretary)
Malcolm Dean (Treasurer)
Ruby Dickens
Tony Heddon - resigned 28 June, 2024
Keith Holmes
Stephen Smith
Debbie Tweddle
Faye Watts
Kate Wheeler (Co-Chair)
Tanya Wood

Independent Examiner	Haines Watts, Statutory Auditor, 3 rd Floor Pacific Chambers, 11-13 Victoria Street, Liverpool, L2 5QQ
----------------------	---

Bankers	Barclays Bank PLC, Newmarket, LE87 2BB
---------	--

Public Benefit Requirement

The trustees of Neuroblastoma UK confirm that they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties.

Section B Structure, governance and management

Governing Document

The Trust is an unincorporated trust, constituted under a Trust Deed dated 20 May, 1983 and by the supplemental Deed of Amendment 9th September 2016 and is a registered Charity number 326385 in England and Wales.

Recruitment and appointment of new trustees

Lay Trustees are appointed by the Trustees following consideration of applications received from individuals. Medical Trustees are appointed by the Trustee on the recommendation of existing Medical Trustees.

Risk Management

Trustees have considered the major risks to which the Charity may be exposed; have reviewed them and established systems and procedures to manage them. Trustees consider the possibility that money placed on investment could be at risk if the organisation holding the deposit should fail. Although current investments are placed with large, well-established financial institutions Trustees identified the need to re-examine investment policy and have concluded that investments should be spread across a number of institutions to minimise the

impact if a single fund-holder should fail. The Trust is essentially a cash based charity, holding no property. The Charity has developed sufficient internal controls to monitor and minimise the risk of misappropriation of funds.

Section C Objectives and activities

Objectives and Aims

The object of the Charity is to improve treatments and outcomes for all children suffering with neuroblastoma, and to achieve this we raise funds for vital medical research. The Charity also raises awareness of the disease, advocates for improved accessibility to treatments and provides information and support to families.

Policy on Grant-Making

Trustees invite applications for grant award by public advertisement, typically on the Charity's website. Normally this is biennially so that sufficient funds are available to commission meaningful research studies, although exceptions are occasionally made when judged appropriate by the Trustees in consultation with the Charity's Scientific Advisory Board (SAB). Applications are first considered by the Charity's SAB, which is made up of 5 scientists experienced in Neuroblastoma research and a chairman who is a paediatric oncology clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist knowledge of the research area proposed, and by a response from the applicants to those reports. The SAB then recommends to Trustees applications worthy of grant funding in order of merit. Trustees award grants in the light of the SAB's advice and funds available. Grants are only awarded to the extent that resources have already accrued in the Charity's unrestricted fund or appropriate restricted fund.

Section D Achievements and performance

Charitable Activities

Thanks to the ongoing generosity of our supporters, we have made key strides in our mission in 2024.

In March, after a break due to the Covid-19 pandemic, we proudly hosted our sixth Neuroblastoma Symposium, which sold out three months in advance. With support from sponsors Julie & Neil Record, Norgine, The Company of Biologists, Cancer Research UK: Cambridge Centre and EUSA Pharma, we welcomed delegates from around the world to Clare College, Cambridge for a dynamic and insightful programme focused on advancing neuroblastoma research. Attendees engaged in robust discussions on a wide range of topics including: protein degraders, developmental plasticity, preclinical evaluation of immunotherapies, epigenetic control, the tumour microenvironment, immunotherapy, and ALK-targeted therapies. It was particularly rewarding to see clusters of researchers continuing conversations and sharing further ideas outside the formal discussions.

This year we were delighted to be able to provide funding for five new research studies totalling £1.1 million. The call for applications was launched at our March 2024 Symposium, generating an unprecedented number of 'excellent' proposals. Total funding requests exceeding £3 million were submitted, and after months of consultation from independent experts and careful review by our Scientific Advisory Board, we were pleased to confirm funding for over a third of the proposals in November 2024. The details of these grants are on our website, and we look forward to reporting on the progress and outcomes of these new exciting projects.

As a charity, we have not been immune to the broader challenges facing our sector in 2024, including a decline in the overall percentage of the population donating to charity and ongoing pressures such as the cost-of-living crisis. Our total income performance steadied in 2024 at £303,350 (£450,434: 2023). We will not be daunted, and remain incredibly humbled by our community's enduring commitment to raise funds and we hope to build on our successes into 2025.

We were pleased to receive our second grant from the Medical Research Council, in 2024 for £89,887, supporting early-career researchers following pandemic-related sector losses. We also thank the Somerset Masonic Lodge, Childwick Trust, Dr Alan Stranders and the IMP Trust for their generous donations.

We continue to be inspired by our passionate community fundraisers, including Ben Sharp and Northwood 41 Club who raised funds through their Santa Collection; the TedFest family who set up a festival in memory of Ted; to Joanne, Andrew and Jen who organised Remembering Reggie Day, and Max, aged 3, who was recently diagnosed with neuroblastoma and has since become a passionate fundraiser supporting our work. Also to Ranby Houses School who donated from the proceeds of two songs, and to the Princes Golf Club, Nick Bushell and Hove Park Tennis Club for their fantastic contributions.

We are especially grateful to Georgia's Fund, who provided match funding for our second successful 'Big Give Christmas Challenge', doubling public donations and raising £12,355 with the support of our Patron Alan Carr. Several brave individuals took on personal challenges to fundraise for Neuroblastoma UK in 2024, and we extend our heartfelt gratitude to each and every one for their commitment. Among many others: Tracy, George, Christine, Gemma and Paul ran the 2024 London Marathon; Sam completed the Great North Run; our own trustee Steve ran the London Landmarks Half Marathon; Carolyn completed the Glasgow Kiltwalk and Jake ran the Edinburgh Marathon. Thank you to every other person who ran, swam, cycled, trekked and more in 2024. We also thank Aurora Managed Services Ltd, who selected Neuroblastoma UK as their Charity of the Year, raising £3,701.01 through raffles, bake sales, and a Christmas Quiz.

Wider support continues to come from our group of generous monthly donors, lottery players, and those who purchase our merchandise. Finally we are deeply appreciative to our Patrons Alan Carr, Angellica Bell, Scott Mills and Charlotte Moore for their continued advocacy and passion.

As part of our advocacy work, we continued our collaboration with the #OneCancerVoice coalition in 2024 and campaigned during the July General Election for a cross-party, long-term cancer strategy. We also continued our collaboration with Solving Kids' Cancer (SKC), participating in their first Parliamentary reception for the launch of their "Kids Get Cancer Too" manifesto.

While our mission is to find a cure for neuroblastoma for all children, we remain dedicated to supporting families currently affected. We distribute free resources, including our "Parents' Guide to Neuroblastoma" and "Treatment Options for Relapsed or Refractory High-Risk Neuroblastoma", both available online and in print in partnership with the Children's Cancer and Leukaemia Group.

The outcomes of the research we fund are published in peer-reviewed journals, presented at national and international conferences, and, where possible, shared through our website and social media. All annual and final research reports are reviewed by our Scientific Advisory Board to ensure accountability and impact.

We would like to give special thanks to Prof. Andy Pearson who has been involved with Neuroblastoma UK in a number of different guises from Patron, Research Trustee and most recently Co-Chair but retired at the end of 2024. Andy has dedicated his professional life to improving outcomes for children with neuroblastoma and as a volunteer, and we have been very privileged to work alongside him.

Due to the generous support of every single one of our fundraisers and donors, 2024 allowed us to make a significant investment into some excellent research programmes and enabled us to reach a wider scientific audience through the Neuroblastoma Symposium; fostering international collaboration and furthering much needed research. We were able to carry out these activities through the kind donation of time from medical and scientific experts, our Scientific Advisory Board, Symposium Planning Board, Patrons, Trustees, volunteers and supporters - thank you all.

Section E Financial review

Reserves Policy

The annual income generated by the Charity is to be applied for charitable purposes in accordance with the Trust's objective. Year on year the trustees intend to make a full distribution of available income, subject to making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research, but not immediately required are invested in line with the investment policy described below. The balance held as unrestricted reserves at 31 December, 2024 was negative £295,947 (2023: £586,048).

Investment Policy

The Trustees' intention is to maintain funds so that they are readily accessible when required, but are earning a reasonable return whilst not utilised. Trustees reviewed this policy in February 2005 and confirmed their policy of only placing funds in investments where the book value of the principal is maintained.

Statement of Trustees Responsibilities

The trustees are responsible for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity Law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with the United Kingdom generally accepted accounting practice (United Kingdom Accounting Standards, comprising FRS 102 'The financial reporting standard applicable in the UK and Republic of Ireland', and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for that period. In preparing those financial statements the trustees are required to:

- ❖ select suitable accounting policies and then apply them consistently;
- ❖ observe the methods and principles in the Charities SORP (FRS102);
- ❖ make judgements and estimates that are reasonable and prudent;
- ❖ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- ❖ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy the financial position of the Charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed.

They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Trustees at a Zoom meeting on 2 May, 2024

Signed on their behalf and with their approval by:

MRS Z AITCHISON
Chair

MR M DEAN
Trustee and Treasurer

Independent Examiner's Report to the Trustees of Neuroblastoma UK

I report to the trustees on the examination of the accounts of Neuroblastoma UK for the year ended 31 December, 2024.

Respective Responsibilities of Trustees and Examiner

The Charity's trustees are responsible for the preparation of accounts in accordance with the requirements of the Charities Act 2011.

I have reported in respect of the examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out the examination have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

The Charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW.

I have completed the examination and can confirm that no material matters have come to my attention in connection with the examination, which gives me reasonable cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act 2011;
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mr M J Forshaw BA FCA
Haines Watts
Pacific Chambers
11-13 Victoria Street
Liverpool
L2 5QQ

NEUROBLASTOMA UK

STATEMENT OF FINANCIAL ACTIVITIES

YEAR ENDED 31 DECEMBER, 2024

	Note	Unrestricted Funds 31 December, 2024 £	Unrestricted Funds 31 December, 2023 £
INCOME AND ENDOWMENTS FROM:			
Donations	2	209,846	366,478
Other trading activities	3	46,985	51,607
Income from investments	4	46,519	32,349
TOTAL		303,350	450,434
 EXPENDITURE ON:			
Raising funds	5	(464)	(6,699)
Charitable activities:			
Grants payable and grant amendments	6	(1,012,496)	214,525
Governance costs	7	(172,385)	(144,403)
TOTAL		(1,185,345)	63,423
NET INCOME/(EXPENDITURE)		(881,995)	513,857
RECONCILIATION OF FUNDS			
Total funds brought forward		586,048	72,191
TOTAL FUNDS CARRIED FORWARD		(295,947)	586,048

NEUROBLASTOMA UK

BALANCE SHEET

AS AT 31 DECEMBER, 2024

	Note	2024 £	2023 £
CURRENT ASSETS			
Debtors and advance payments	9	24,663	46,341
Investments	10	1,250,792	967,476
Cash at bank	11	100,743	378,268
TOTAL CURRENT ASSETS		1,376,198	1,392,085
CREDITORS: Amounts falling due within one year	12	(483,564)	(655,329)
NET CURRENT ASSETS		892,634	736,756
CREDITORS: Amounts falling due in more than one year	13,14	(1,188,581)	(150,708)
NET ASSETS		(295,947)	586,048
FUNDS OF THE CHARITY			
Unrestricted fund	15	(295,947)	586,048

The financial statements set out on pages 8 – 13 were approved by the Trustees on 19 May, 2025

TRUSTEE – Mrs Z Aitchison

TRUSTEE – Mr M Dean

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER, 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable trust, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015)', the Financial Reporting Standard 102 (effective January 2015) and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Donations

Cash donations and gifts are included in full in the Statement of Financial Activities when they are received by the Charity. Cash collected at special fund-raising events is included in the income and expenditure account after deducting the expenditure incurred directly in staging the event. Significant non-cash donations are included in the income and expenditure account at the Trustees' estimation of their market value when received.

Income from investments

Investment income is included in the Statement of Financial Activities on an accruals basis.

Research grant awards

These are charged to the Statement of Financial Activities when the Trustees have awarded them. Research grants awarded, but not disbursed at the balance sheet date, are carried forward as grant creditors in the balance sheet.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Cash flow statements

The Charity has taken advantage of the exemption provided by the Charities SORP (FRS102) and does not prepare a cash flow statement.

Taxation

The Charity is exempt from taxation on its charitable activities.

VAT

As a non-trading organisation the Charity is not registered for VAT purposes, and is unable to recover VAT incurred on its expenditure.

NEUROBLASTOMA UK
NOTES TO THE ACCOUNTS (Continued)
YEAR ENDED 31 DECEMBER, 2024

2. DONATIONS

	2024	2023
	£	£
Donations and fund-raising	209,846	366,478

3. OTHER TRADING ACTIVITIES

	2024	2023
	£	£
Christmas cards, webshop and other income	46,985	51,607

4. INCOME FROM INVESTMENTS

	2024	2023
	£	£
COIF deposit	33,315	27,728
National savings income bonds	12,204	4,621
	46,519	32,349

5. EXPENDITURE ON RAISING FUNDS

	2024	2023
	£	£
Fund-raising and publicity costs	464	6,699

6. GRANTS PAYABLE AND GRANT MOVEMENTS

	2024	2023
	£	£
Contribution from Medical Research Council	(89,857)	(214,525)
Archibald	268,301	
Chesler	254,120	
Falconer	188,039	
Piskareva	208,887	
Stoker	183,207	
Written off	(201)	
	1,012,496	(214,525)

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS (Continued)

YEAR ENDED 31 DECEMBER, 2024

7. EXPENDITURE ON CHARITABLE ACTIVITIES

	2024	2023
	£	£
Staff salaries and pension contributions	96,012	87,803
Rent and facilities	8,573	8642
Sporting event costs	5,407	8,757
Cambridge Symposium	38,893	
Trustees meeting costs	714	213
Subscriptions	4,734	2,618
Computers, software and equipment hire	9,027	8,439
40 th Anniversary celebration	0	3,307
Accounts and audit	840	7
Legal fees	1,869	
Printing, postage and stationery	262	585
Sundries	1,926	414
Advertising and website	1,944	1,903
Insurance	1,202	1,155
Bank and professional charges	982	135
Staff training	0	131
ANR Conference	0	18,366
	172,385	144,403

8. TRUSTEES' REMUNERATION AND BENEFITS

There was no trustees' remuneration or other benefits for the year ended 31 December, 2024 (2023: £NIL).

The Trust owns no premises.

9. DEBTORS AND PREPAYMENTS

	2024	2023
	£	£
Receivables	1,188	1,188
Prepayments	4,226	22,403
Co-funding income	19,250	24,750
	24,663	46,341

10. CURRENT INVESTMENTS

	2024	2023
	£	£
COIF Deposit Fund	900,792	617,476
National Savings – Income bonds	350,000	350,000
	1,250,792	967,476

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS (Continued)

YEAR ENDED 31 DECEMBER, 2024

11. CASH AT BANK AND IN HAND

	2024	2023
	£	£
Cash at Bank	100,742	378,268

12. CREDITORS – DUE WITHIN ONE YEAR

	2024	2023
	£	£
Grant commitments	465,696	548,847
Trade creditors	1,966	90,582
Accruals	900	900
Co-funding income received in advance	15,000	15,000
	483,563	655,329

13. CREDITORS – DUE IN MORE THAN ONE YEAR

	2024	2023
	£	£
Grant commitments	1,188,581	150,708

14. GRANT COMMITMENTS

	2024	2023
	£	£
Total commitments at 1 January, 2024	670,328	1,060,435
Paid in the year	(118,403)	(373,668)
New commitments	1,102,554	12,788
	1,654,479	699,555

All of the grants paid in 2024 and 2023 were to institutions and to commission research studies.
All of the new grant commitments in 2024 were to institutions.

15. ANALYSIS OF UNRESTRICTED FUND

	2024	2023
	£	£
At 1 January, 2024	586,048	72,191
Net movement in funds for the year	(881,995)	513,857
	(295,946)	586,048

Accounts



NEUROBLASTOMA UK

Charity Commission reference number
326385

REPORTS AND FINANCIAL STATEMENTS

For the year ended 31 December, 2023

NEUROBLASTOMA UK

REPORT AND FINANCIAL STATEMENTS

For the year ended 31 December, 2023

CONTENTS

	Page
Trustees' annual report	2-5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance sheet	8
Notes to the financial statements	9-12

TRUSTEES' ANNUAL REPORT for the year to 31 December, 2023

The Trustees present their report with the financial statements of the Charity for the year ended 31 December, 2023. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015). As a charity registered in England and Wales, the Charity also reports in accordance with the Charity Commission for England and Wales' guidance on public benefit and the Charities Act 2015.

Section A Reference and administrative details

Charity Name	NEUROBLASTOMA UK
Registered Charity Number	326385
Registered Address	7-14 Great Dover Street, London SE1 4YR

Trustees who manage the Charity:

Zara Aitchison (Co-Chair)
Andy Pearson (Co-Chair)
Tori Eadington (Secretary) – appointed 10 September 2023
Malcolm Dean (Treasurer)
Ruby Dickens
Tony Heddon
Keith Holmes
Stephen Smith
Debbie Tweddle
Faye Watts
Kate Wheeler (Co-Chair)
Tanya Wood - appointed 27 May 2023
Carolyn Jackson - resigned

Independent Examiner	Haines Watts, Statutory Auditor, 3 rd Floor Pacific Chambers, 11-13 Victoria Street, Liverpool, L2 5QQ
----------------------	---

Bankers	Barclays Bank PLC, Newmarket, LE87 2BB
---------	--

Public Benefit Requirement

The trustees of Neuroblastoma UK confirm that they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties.

Section B Structure, governance and management

Governing Document

The Trust is an unincorporated trust, constituted under a Trust Deed dated 20 May, 1983 and by the supplemental Deed of Amendment 9th September 2016 and is a registered Charity number 326385 in England and Wales.

Recruitment and appointment of new trustees

Lay Trustees are appointed by the Trustees following consideration of applications received from individuals. Medical Trustees are appointed by the Trustee on the recommendation of existing Medical Trustees.

Risk Management

Trustees have considered the major risks to which the Charity may be exposed; have reviewed them and established systems and procedures to manage them. Trustees consider the possibility that money placed on investment could be at risk if the organisation holding the deposit should fail. Although current investments are placed with large, well-established financial institutions Trustees identified the need to re-examine investment policy and have concluded that investments should be spread across a number of institutions to minimise the

impact if a single fund-holder should fail. The Trust is essentially a cash based charity, holding no property. The Charity has developed sufficient internal controls to monitor and minimise the risk of misappropriation of funds.

Section C Objectives and activities

Objectives and Aims

The object of the Charity is to improve treatments and outcomes for all children suffering with neuroblastoma, and to achieve this we raise funds for vital medical research. The Charity also raises awareness of the disease, advocates for improved accessibility to treatments and provides information and support to families.

Policy on Grant-Making

Trustees invite applications for grant award by public advertisement, typically on the Charity's website. Normally this is biennially so that sufficient funds are available to commission meaningful research studies, although exceptions are occasionally made when judged appropriate by the Trustees in consultation with the Charity's Scientific Advisory Board (SAB). Applications are first considered by the Charity's SAB, which is made up of 5 scientists experienced in Neuroblastoma research and a chairman who is a paediatric oncology clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist knowledge of the research area proposed, and by a response from the applicants to those reports. The SAB then recommends to Trustees applications worthy of grant funding in order of merit. Trustees award grants in the light of the SAB's advice and funds available. Grants are only awarded to the extent that resources have already accrued in the Charity's unrestricted fund or appropriate restricted fund.

Section D Achievements and performance

Charitable Activities

With the residual ongoing challenges from the pandemic and the tougher economic environment, 2023 has been a year to replenish funds to build towards hosting a Neuroblastoma UK Symposium and Major Grant Round in 2024. However we did still fund new research, we cofunded with Solving Kids Cancer for the development and initial start-up costs of the REDMAPP study website led by Helen Pearson and additional funding of a research project being carried out by Prof Suzanne Turner at Cambridge investigating into personalised therapeutics to prevent and treat anaplastic lymphoma kinase (ALK) positive neuroblastoma resistant to ALK inhibitors. Also, Neuroblastoma UK were one of the main sponsors for the International Conference in Amsterdam for the Advances in Neuroblastoma Research bringing together researchers from around the world with introductory educational sessions, presentations on the latest trials and insight into some of the basic science work being undertaken in the neuroblastoma research field. For the first time in the history of the Conference, patient advocates were a part of the main agenda and our Trustee, Stephen Smith joined other patient advocates on the panel to discuss, with questions posed by clinicians, as to how patient advocates can help improve the survival of children with Neuroblastoma.

2023 saw us hold our first advocacy event in Scotland during Children's Cancer Awareness Month, kindly hosted by Rona Mackay SNP in memory of Matthew Innes and calling on MSPs to ensure that childhood cancer is recognised as a critical research priority in Scotland and supported by members of the Scottish paediatric medical community. This was a very special and moving reception highlighting the impact of a childhood cancer diagnosis and the need for more research.

Earlier in the year we marched, with a number of other cancer charities, as 'One Cancer Voice' to hand a petition to 10 Downing Street, London calling on the government to improve outcomes and experiences for people affected with cancer.

We have worked closer with Solving Kids Cancer in 2023 looking at ways that we can work better on behalf of all children with neuroblastoma and their families and to ensure that all areas across the research spectrum receive the awareness and vital funding needed.

2023 showed a stronger financial position to 2022, in part to the £214,000 we received from the UK Government/ Medical Research Fund for charity funded early career researchers.

We are a charity reliant on voluntary income through fundraising. This is the key to our vital research and we are extremely grateful to our supporters who ran marathons, climbed mountains, dusted off their football boots, baked, sang and numerous other activities to raise money for our cause.

We received additional support in 2023 from a number of charity partners including Georgia's Fund, Vitol Foundation and Isabelle Grundy Donations Trust . We also worked with a number of corporate partners including Banks Group, Rightway Electrical, Topling Ltd, Solent Stevedores and Rosebuds & Pearls.

Additional fundraising activities from the Charity came in the launch of our weekly Lottery draw and our first time participation in the Big Give - Christmas Challenge , a match funded charity campaign .

We continued to distribute our free "Parents Guide to Neuroblastoma" and our factsheet "Treatment options for relapsed or refractory high risk neuroblastoma", online and in print, in collaboration with Children's Cancer and Leukaemia Group.

The outcomes of the research we fund are published in peer-reviewed journals and where possible referenced on our website and social media platforms. Publications are also shared with other researchers at national and international meetings of researchers. Annual and Final research reports are examined and assessed by our Scientific Advisory Board .

Our sincere thanks for the continued support of fundraisers, families, researchers, expert advisers, volunteers, patrons, staff and trustees of Neuroblastoma UK in 2023.

Section E Financial review

Reserves Policy

The annual income generated by the Charity is to be applied for charitable purposes in accordance with the Trust's objective. Year on year the trustees intend to make a full distribution of available income, subject to making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research, but not immediately required are invested in line with the investment policy described below. The balance held as unrestricted reserves at 31 December, 2023 was £586,048 (2022: £72,191).

Investment Policy

The Trustees' intention is to maintain funds so that they are readily accessible when required, but are earning a reasonable return whilst not utilised. Trustees reviewed this policy in February 2005 and confirmed their policy of only placing funds in investments where the book value of the principal is maintained.

Statement of Trustees Responsibilities

The trustees are responsible for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity Law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with the United Kingdom generally accepted accounting practice (United Kingdom Accounting Standards, comprising FRS 102 'The financial reporting standard applicable in the UK and Republic of Ireland', and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for that period. In preparing those financial statements the trustees are required to:

- ❖ select suitable accounting policies and then apply them consistently;
- ❖ observe the methods and principles in the Charities SORP (FRS102);
- ❖ make judgements and estimates that are reasonable and prudent;
- ❖ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- ❖ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy the financial position of the Charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed.

They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Trustees at a Zoom meeting on 2 May, 2024

Signed on their behalf and with their approval by:

MRS Z AITCHISON
Chair

MR M DEAN
Trustee and Treasurer

Independent Examiner's Report to the Trustees of Neuroblastoma UK

I report to the trustees on the examination of the accounts of Neuroblastoma UK for the year ended 31 December, 2023.

Respective Responsibilities of Trustees and Examiner

The Charity's trustees are responsible for the preparation of accounts in accordance with the requirements of the Charities Act 2011.

I have reported in respect of the examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out the examination have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

The Charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW.

I have completed the examination and can confirm that no material matters have come to my attention in connection with the examination, which gives me reasonable cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act 2011;
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mr M J Forshaw BA FCA
Haines Watts
Pacific Chambers
11-13 Victoria Street
Liverpool
L2 5QQ

NEUROBLASTOMA UK

STATEMENT OF FINANCIAL ACTIVITIES

YEAR ENDED 31 DECEMBER, 2023

	Note	Unrestricted Funds 31 December, 2023 £	Unrestricted Funds 31 December, 2022 £
INCOME AND ENDOWMENTS FROM:			
Donations	2	366,478	250,365
Other trading activities	3	51,607	9,340
Income from investments	4	32,349	8,712
TOTAL		450,434	268,417
EXPENDITURE ON:			
Raising funds	5	(6,699)	(7,506)
Charitable activities:			
Grants payable and grant amendments	6	214,525	(691,520)
Governance costs	7	(144,403)	(119,754)
TOTAL		63,423	(818,780)
NET INCOME/(EXPENDITURE)		513,857	(550,363)
RECONCILIATION OF FUNDS			
Total funds brought forward		72,191	622,554
TOTAL FUNDS CARRIED FORWARD		586,048	72,191

NEUROBLASTOMA UK

BALANCE SHEET

AS AT 31 DECEMBER, 2023

	Note	2023 £	2022 £
CURRENT ASSETS			
Debtors and advance payments	9	46,341	55,176
Investments	10	967,476	845,713
Cash at bank	11	378,268	275,392
TOTAL CURRENT ASSETS		1,392,085	1,176,281
CREDITORS: Amounts falling due within one year	12	(655,329)	(605,785)
NET CURRENT ASSETS		736,756	570,496
CREDITORS: Amounts falling due in more than one year	13,14	(150,708)	(498,305)
NET ASSETS		586,048	72,191
FUNDS OF THE CHARITY			
Unrestricted fund	15	586,048	72,191

The financial statements set out on pages 8 – 13 were approved by the Trustees on

TRUSTEE – Mrs Z Aitchison

TRUSTEE – Mr M Dean

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER, 2023

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable trust, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015)', the Financial Reporting Standard 102 (effective January 2015) and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Donations

Cash donations and gifts are included in full in the Statement of Financial Activities when they are received by the Charity. Cash collected at special fund-raising events is included in the income and expenditure account after deducting the expenditure incurred directly in staging the event. Significant non-cash donations are included in the income and expenditure account at the Trustees' estimation of their market value when received.

Income from investments

Investment income is included in the Statement of Financial Activities on an accruals basis.

Research grant awards

These are charged to the Statement of Financial Activities when the Trustees have awarded them. Research grants awarded, but not disbursed at the balance sheet date, are carried forward as grant creditors in the balance sheet.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Cash flow statements

The Charity has taken advantage of the exemption provided by the Charities SORP (FRS102) and does not prepare a cash flow statement.

Taxation

The Charity is exempt from taxation on its charitable activities.

VAT

As a non-trading organisation the Charity is not registered for VAT purposes, and is unable to recover VAT incurred on its expenditure.

2. DONATIONS

3. OTHER TRADING ACTIVITIES

4. INCOME FROM INVESTMENTS

5. EXPENDITURE ON RAISING FUNDS

6. GRANTS PAYABLE AND GRANT AMENDMENTS

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS (Continued)

YEAR ENDED 31 DECEMBER, 2023

7. EXPENDITURE ON CHARITABLE ACTIVITIES

	2023	2022
	£	£
Rent and facilities	8,642	8,923
Staff salaries and pension contributions	87,803	67,118
Staff training	131	0
Sporting event costs	8,757	8,566
Subscriptions	2,618	2,183
Travel	1,215	177
Computers, software and equipment hire	8,439	5,195
40 th Anniversary celebration	3,307	11,792
Accounts and audit	720	5,556
Trustees meeting costs	213	0
Printing, postage and stationery	585	1,456
Sundries	414	1,727
Advertising and website	1,903	5,870
Insurance	1,155	1,119
Bank and professional charges	135	72
ANR Conference	18,366	0
	144,403	119,754

8. TRUSTEES' REMUNERATION AND BENEFITS

There was no trustees' remuneration or other benefits for the year ended 31 December, 2023 (2022: £NIL).

The Trust owns no premises.

9. DEBTORS AND PREPAYMENTS

	2023	2022
	£	£
Receivables	1,188	1,188
Prepayments	20,403	23,238
Co-funding income	24,750	30,750
	46,341	55,176

10. CURRENT INVESTMENTS

	2023	2022
	£	£
COIF Deposit Fund	617,476	495,713
National Savings – Income bonds	350,000	350,000
	967,476	845,713

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS (Continued)

YEAR ENDED 31 DECEMBER, 2023

11. CASH AT BANK AND IN HAND

	2023	2022
	£	£
Cash at Bank	378,268	275,392

12. CREDITORS – DUE WITHIN ONE YEAR

	2023	2022
	£	£
Grant commitments	548,847	562,130
Trade creditors	90,582	27,755
Accruals	900	900
Co-funding income received in advance	15,000	15,000
	655,329	605,785

13. CREDITORS – DUE IN MORE THAN ONE YEAR

	2023	2022
	£	£
Grant commitments	150,708	498,305

14. GRANT COMMITMENTS

	2023	2022
	£	£
Total commitments at 1 January, 2023	1,060,435	682,189
Paid in the year	(373,668)	(298,275)
New commitments	12,788	676,523
Written back in the year		(2)
	699,555	1,060,435

All of the grants paid in 2023 and 2022 were to institutions and to commission research studies.
All of the new grant commitments in 2023 were to institutions.

15. ANALYSIS OF UNRESTRICTED FUND

	2023	2022
	£	£
At 1 January, 2023	72,191	622,554
Net movement in funds for the year	513,857	(550,363)
	586,048	72,191

Accounts



NEUROBLASTOMA UK

Charity Commission reference number
326385

REPORTS AND FINANCIAL STATEMENTS

For the year ended 31 December, 2022

NEUROBLASTOMA UK

REPORT AND FINANCIAL STATEMENTS

For the year ended 31 December, 2022

CONTENTS

	Page
Trustees' annual report	3-6
Independent Examiner's Report	7
Statement of financial activities	8
Balance sheet	9
Notes to the financial statements	10-13

TRUSTEES' ANNUAL REPORT for the year to 31 December, 2022

The Trustees present their report with the financial statements of the charity for the year ended 31 December, 2022. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015). As a charity registered in England and Wales, the charity also reports in accordance with the Charity Commission for England and Wales' guidance on public benefit and the Charities Act 2015.

Section A Reference and administrative details

Charity Name	NEUROBLASTOMA UK
Registered Charity Number	326385
Registered Address	7/14 Great Dover Street, London SE1 4YR

Trustees who manage the charity:

Tony Heddon (Chair)
Carolyn Jackson (Secretary)
Malcolm Dean (Treasurer)
Zara Aitchison
Ruby Dickens
Keith Holmes
Jane Morris
Andy Pearson
Monica Proctor
Stephen Smith
Debbie Tweddle
Faye Watts
Kate Wheeler
Alastair Whittington (resigned December 2022)

Independent Examiner	Haines Watts, Statutory Auditor, 3 rd Floor Pacific Chambers, 11-13 Victoria Street, Liverpool, L2 5QQ
----------------------	---

Bankers	Barclays Bank PLC, Newmarket, LE87 2BB
---------	--

Public Benefit Requirement

The trustees of Neuroblastoma UK confirm that they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties.

Section B Structure, governance and management

Governing Document

The Trust is an unincorporated trust, constituted under a Trust Deed dated 20 May, 1983 and is a registered Charity number 326385.

Recruitment and appointment of new trustees

Lay Trustees are appointed by the Trustees following consideration of applications received from individuals. Medical Trustees are appointed by the Trustee on the recommendation of existing Medical Trustees.

Risk Management

Trustees have considered the major risks to which the charity may be exposed; have reviewed them and established systems and procedures to manage them. Trustees consider the possibility that money placed on investment could be at risk if the organisation holding the deposit should fail. Although current investments are placed with large, well-established financial institutions Trustees identified the need to re-examine investment policy and have concluded that investments should be spread across a number of institutions to minimise the

impact if a single fund-holder should fail. The Trust is essentially a cash based charity, holding no property. The Charity has developed sufficient internal controls to monitor and minimise the risk of misappropriation of funds.

Section C Objectives and activities

Objectives and aims

The object of the Charity is to provide relief for children suffering from Neuroblastoma, and to achieve this, it raises funds for medical research into improving both diagnosis and treatment of the disease. The Charity also offers an opportunity for parents to give each other mutual help, support and comfort.

Policy on Grant-making

Trustees invite applications for grant award by public advertisement, typically on the Charity's website. Normally this is biennially so that sufficient funds are available to commission meaningful research studies, although exceptions are occasionally made when judged appropriate by the Trustees in consultation with the Charity's Scientific Advisory Board (SAB). Applications are first considered by the Charity's SAB, which is made up of 5 scientists experienced in Neuroblastoma research and a chairman who is a paediatric oncology clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist knowledge of the research area proposed, and by a response from the applicants to those reports. The SAB then recommends to Trustees applications worthy of grant funding in order of merit. Trustees award grants in the light of the SAB's advice and funds available. Grants are only awarded to the extent that resources have already accrued in the Charity's unrestricted fund or appropriate restricted fund.

Section D Achievements and performance

Charitable activities

Having completed our bi-annual grant round the previous year, there were few additional research grants allocated. However, we did fund two grants at Southampton hospital

Dr Jinhui Gao - Investigating the role of Enhancer of Zeste homolog 2 and Natural killer cells in neuroblastoma

Dr Rob Ewing - Looking at how the Zika virus kills Neuroblastoma cells? A potential new oncolytic virotherapy for Neuroblastoma

With the on-going delays through COVID, all the 2019 grants received no cost extensions having the effect of lengthening the time we will hold onto these liabilities before payment

As part of our 40th anniversary fundraising activity, our key activities included:

- A comedy night hosted by our Patrons Alan Carr and Angellica Bell at The Rose Theatre in Kingston raised £11,400. Our huge thanks to Alan and Angellica for organising the event and to Off The Kerb Productions.
- We celebrated our anniversary with a special reception in London, which included an art exhibition, online auction and prize draw. The event brought together clinicians, researchers, supporters, charity partners and families affected by neuroblastoma, and raised £18,778.98.
- We launched a range of 40th anniversary merchandise, including pin badges, keyrings, branded sportswear, bottles and bags.
- We worked with Beads of Courage to provide funding for 40 Siblings packs at no cost to the families. The Sibling programme is designed to support and recognise siblings of children with a serious or life-threatening illness.

We launched our first children's design competition for our 2022 Christmas card range. The winning designs were by Lucy, aged 13 and Esme, aged 4 who sadly lost family members to neuroblastoma. and helped to raise £975.

As part of Childhood Cancer Awareness Month in September, we launched our Glow Gold event, encouraging supporters to light a Neuroblastoma UK candle and remember all the children and families affected by neuroblastoma. This new initiative raised over £500.

We worked with a number of corporate partners in 2022, who took part in, or organised, a number of new fundraising events throughout the year. A total of nearly £20,000 was raised by companies including Banks Group, who chose us as their Charity of the Year partner, and Metis Consultants through their Land's End to

John o' Groats challenge. We also launched a new charity video thanks to pro-bono support from Obrizum Media, featuring interviews with researchers and families affected by neuroblastoma. We are also grateful to 3B Digital for their ongoing pro-bono support across our digital channels.

We had our biggest London Marathon team to date in 2022 due to roll over places from the cancelled 2020 event. Our team of 10 runners raised just under £18,000.

We welcomed our third member of paid staff as part of our continued growth and focus on individual giving, community fundraising and challenge events, in a key role of Public Fundraising Manager. Although we saw a drop in income for this area in 2022, this was impacted by reduced staffing resources during the year. With a new Philanthropy and Partnerships Manager role planned for 2023 and a return to full team capacity, we look forward to seeing significant growth in 2023. New initiatives are planned including a new gaming stream consisting of a weekly lottery

We welcomed TV and radio presenter Angellica Bell and Charlie Moore, neuroblastoma survivor and Team GB Paralympian as our new Patrons for 2022. With their passion and personal connection to our cause, alongside our existing Patrons Alan Carr and Scott Mills, we can raise awareness of neuroblastoma to a wider audience.

We continued to distribute our free "Parents Guide to Neuroblastoma" and our factsheet "Treatment options for relapsed or refractory high risk neuroblastoma", online and in print. Both items were updated and reprinted in 2022, in collaboration with Children's Cancer and Leukaemia Group. Our webpage was visited nearly 800 times with nearly 300 downloads. We aim to continue to support print costs for the Parent's Guide in 2023.

Section E Financial Review

Reserves Policy

The annual income generated by the Charity is to be applied for charitable purposes in accordance with the Trust's objective. Year on year the trustees intend to make a full distribution of available income, subject to making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research, but not immediately required are invested in line with the investment policy described below. The balance held as unrestricted reserves at 31 December, 2022 was £72,191 (2021 £622,454).

Investment Policy

The Trustees' intention is to maintain funds so that they are readily accessible when required, but are earning a reasonable return whilst not utilised. Trustees reviewed this policy in February 2005 and confirmed their policy of only placing funds in investments where the book value of the principal is maintained.

Statement of Trustees Responsibilities

The trustees are responsible for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity Law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with the United Kingdom Generally Accepted Accounting Practice (United Kingdom Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for that period. In preparing those financial statements the trustees are required to:

- ☐ select suitable accounting policies and then apply them consistently;
- ☐ observe the methods and principles in the Charities SORP (FRS102)
- ☐ make judgements and estimates that are reasonable and prudent;
- ☐ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- ☐ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy the financial position of the charity and to enable them to ensure that the financial statements comply with the

Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Trustees at a Zoom meeting on 21 July, 2022

Signed on their behalf and with their approval by:

MR T HEDDON
Chair

MR M DEAN
Trustee and Treasurer

Independent Examiner's Report to the Trustees of Neuroblastoma UK

I report to the trustees on the examination of the accounts of Neuroblastoma UK for the year ended 31 December, 2022.

Respective responsibilities of Trustees and Examiner

The charity's trustees are responsible for the preparation of accounts in accordance with the requirements of the Charities Act 2011.

I have reported in respect of the examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out the examination have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

The Charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW.

I have completed the examination and can confirm that no material matters have come to my attention in connection with the examination, which gives me reasonable cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mr M J Forshaw BA FCA
Haines Watts
Pacific Chambers
11-13 Victoria Street
Liverpool
L2 5QQ

NEUROBLASTOMA UK

STATEMENT OF FINANCIAL ACTIVITIES

YEAR ENDED 31 DECEMBER, 2022

	Note	Unrestricted Funds 31 December, 2022		Unrestricted Funds 31 December, 2021	
		£	£	£	£
INCOME AND ENDOWMENTS FROM:					
Donations	2		250,365		387,955
Other trading activities	3		9,339		29,238
Income from investments	4		8,712		130
TOTAL			268,417		417,323
EXPENDITURE ON:					
Raising funds	5	(7,506)		(7,996)	
Charitable activities:					
Grants payable and grant amendments	6	(691,520)		(9,333)	
Governance costs	7	(119,754)		(104,354)	
TOTAL			(818,780)		(121,683)
NET (EXPENDITURE)/INCOME			(550,363)		295,640
RECONCILIATION OF FUNDS					
Total funds brought forward			622,554		326,914
TOTAL FUNDS CARRIED FORWARD			72,191		622,554

NEUROBLASTOMA UK

BALANCE SHEET

AS AT 31 DECEMBER, 2022

	Note	2022 £	2021 £
CURRENT ASSETS			
Debtors and advance payments	9	55,176	20,515
Investments	10	845,713	959,763
Cash at bank	11	275,392	362,384
TOTAL CURRENT ASSETS		1,176,281	1,342,662
CREDITORS: Amounts falling due within one year	12	(605,785)	(480,230)
NET CURRENT ASSETS		570,496	862,432
CREDITORS: Amounts falling due in more than one year	13,14	(498,305)	(239,877)
NET ASSETS		72,191	622,554
FUNDS OF THE CHARITY			
Unrestricted fund	15	72,191	622,554

The financial statements set out on pages 8 – 13 were approved by the Trustees on

TRUSTEE – Mr T Heddon

TRUSTEE – Mr M Dean

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER, 2022

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable trust, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015)', the Financial Reporting Standard 102 (effective January 2015) and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Donations

Cash donations and gifts are included in full in the Statement of Financial Activities when they are received by the charity. Cash collected at special fund-raising events is included in the income and expenditure account after deducting the expenditure incurred directly in staging the event. Significant non-cash donations are included in the income and expenditure account at the Trustees' estimation of their market value when received.

Income from investments

Investment income is included in the Statement of Financial Activities on an accruals basis.

Research Grant Awards

These are charged to the Statement of Financial Activities when the Trustees have awarded them. Research grants awarded, but not disbursed at the balance sheet date, are carried forward as grant creditors in the balance sheet.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Cash Flow Statements

The Charity has taken advantage of the exemption provided by the Charities SORP (FRS102) and does not prepare a cash flow statement.

Taxation

The charity is exempt from Taxation on its charitable activities.

VAT

As a non-trading organisation the charity is not registered for VAT purposes, and is unable to recover VAT incurred on its expenditure.

NEUROBLASTOMA UK
NOTES TO THE ACCOUNTS (Continued)
YEAR ENDED 31 DECEMBER, 2022

2.	DONATIONS	2022	2021
		£	£
	Donations and fund-raising	250,365	387,955
3.	OTHER TRADING ACTIVITIES	2022	2021
		£	£
	Job Retention Scheme grant		750
	Christmas cards, webshop and other income	9,339	28,488
		9,339	29,238
4.	INCOME FROM INVESTMENTS	2022	2021
		£	£
	COIF deposit	5,949	72
	National savings income bonds	2,763	58
		8,712	130
5.	EXPENDITURE ON RAISING FUNDS	2022	2021
		£	£
	Fund-raising and publicity costs	7,506	7,996
6.	GRANTS PAYABLE AND GRANT AMENDMENTS	2022	2021
		£	£
	University of Birmingham		4,981
	Gaze	214,385	
	Chesler	469,093	
	Ewing & Gao	10,000	
	Conferences, Travel and Other Grants		9,333
	Write back	(1,958)	(4,981)
		691,520	9,333
7.	EXPENDITURE ON CHARITABLE ACTIVITIES		

	2022 £	2021 £
Rent and facilities	8,923	11,163
Staff salaries and pension contributions	67,118	66,767
Staff training	0	435
Sporting event costs	8,566	902
Subscriptions	2,183	1,622
Travel	177	78
Computers, software and equipment hire	5,195	2,905
40 th Anniversary celebration	11,792	0
Accounts and audit	5,556	10,872
Trustees meeting costs	0	0
Printing, postage and stationery	1,456	604
Sundries	1,727	804
Advertising and website	5,870	6,633
Insurance	1,119	977
Bank and professional charges	72	592
Seminar costs	0	0
	119,754	104,354

8. TRUSTEES' REMUNERATION AND BENEFITS

There was no trustees' remuneration or other benefits for the year ended 31 December, 2022 (2021 £NIL).

The Trust owns no premises.

9. DEBTORS AND PREPAYMENTS

	2022 £	2021 £
Receivables	1,188	1,188
Prepayments	23,238	6,827
Co-funding income	30,750	12,500
	55,176	20,515

10. CURRENT INVESTMENTS

	2022 £	2021 £
COIF Deposit Fund	495,713	609,763
National Savings – Income bonds	350,000	350,000
	845,713	959,763

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS (Continued)

YEAR ENDED 31 DECEMBER, 2022

11. CASH AT BANK AND IN HAND

	2022	2021
	£	£
Cash at Bank	275,392	362,384

12. CREDITORS – DUE WITHIN ONE YEAR

	2022	2021
	£	£
Grant commitments	562,130	442,311
Trade creditors	27,755	22,019
Accruals	900	900
Co-funding income received in advance	15,000	15,000
	605,785	480,230

13. CREDITORS – DUE IN MORE THAN ONE YEAR

	2022	2021
	£	£
Grant commitments	498,305	239,877

14. GRANT COMMITMENTS

	2022	2021
	£	£
Total commitments at 1 January, 2022	682,189	1,001,604
Paid in the year	(298,275)	(319,415)
New commitments	678,478	4,981
Written back in the year	(2)	(4,981)
	1,062,391	682,189

All of the grants paid in 2022 and 2021 were to institutions and to commission research studies.
All of the new grant commitments in 2022 were to institutions.

15. ANALYSIS OF UNRESTRICTED FUND

	2022	2021
	£	£
At 1 January, 2022	622,554	326,914
Net movement in funds for the year	(550,363)	295,640
	72,191	622,554

Accounts



NEUROBLASTOMA UK

Charity Commission reference number
326385

REPORTS AND FINANCIAL STATEMENTS

For the year ended 31 December, 2021

NEUROBLASTOMA UK

REPORT AND FINANCIAL STATEMENTS

For the year ended 31 December, 2021

CONTENTS

	Page
Trustees' annual report	3-5
Independent Examiner's Report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9-12

The Trustees present their report with the financial statements of the charity for the year ended 31 December, 2021. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015). As a charity registered in England and Wales, the charity also reports in accordance with the Charity Commission for England and Wales' guidance on public benefit and the Charities Act 2015.

Charity Name NEUROBLASTOMA UK

Registered Charity Number 326385

Registered Address 7/14 Great Dover Street, London SE1 4YR

Trustees who manage the charity:

Tony Heddon (Chair)
Carolyn Jackson (Secretary)
Malcolm Dean (Treasurer)
Zara Aitchison
Ruby Dickens
Keith Holmes
Jane Morris
Andy Pearson
Monica Proctor
Stephen Smith
Debbie Tweddle
Faye Watts
Kate Wheeler
Alastair Whittington

Independent Examiner Haines Watts, Statutory Auditor, 3rd Floor Pacific Chambers, 11-13
Victoria Street, Liverpool, L2 50Q

Bankers Barclays Bank PLC, Newmarket, LE87 2BB

Public Benefit Requirement

The trustees of Neuroblastoma UK confirm that they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties.

Section B Structure, governance and management

Governing Document

The Trust is an unincorporated trust, constituted under a Trust Deed dated 20 May, 1983 and is a registered Charity number 326385.

Recruitment and appointment of new trustees

Lay Trustees are appointed by the Trustees following consideration of applications received from individuals. Medical Trustees are appointed by the Trustee on the recommendation of existing Medical Trustees.

Risk Management

Trustees have considered the major risks to which the charity may be exposed; have reviewed them and established systems and procedures to manage them. Trustees consider the possibility that money placed on investment could be at risk if the organisation holding the deposit should fail. Although current investments are placed with large, well-established financial institutions Trustees identified the need to re-examine investment policy and have concluded that investments should be spread across a number of institutions to minimise the impact if a single fund-holder should fail. The Trust is essentially a cash based charity, holding no property. The Charity has developed sufficient internal controls to monitor and minimise the risk of misappropriation of funds.

Section C Objectives and activities

Objectives and aims

The object of the Charity is to provide relief for children suffering from Neuroblastoma, and to achieve this, it raises funds for medical research into improving both diagnosis and treatment of the disease. The Charity also offers an opportunity for parents to give each other mutual help, support and comfort.

Policy on Grant-making

Trustees invite applications for grant award by public advertisement, typically on the Charity's website. Normally this is biennially so that sufficient funds are available to commission meaningful research studies, although exceptions are occasionally made when judged appropriate by the Trustees in consultation with the Charity's Scientific Advisory Board (SAB). Applications are first considered by the Charity's SAB, which is made up of 5 scientists experienced in Neuroblastoma research and a chairman who is a paediatric oncology clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist knowledge of the research area proposed, and by a response from the applicants to those reports. The SAB then recommends to Trustees applications worthy of grant funding in order of merit. Trustees award grants in the light of the SAB's advice and funds available. Grants are only awarded to the extent that resources have already accrued in the Charity's unrestricted fund or appropriate restricted fund.

Section D Achievements and performance

Charitable activities

Postponed due to the coronavirus pandemic, Neuroblastoma UK completed our biennial research Grant Round for 2021 in April. The charity received seven research applications totalling £2.48million from 12 countries. Following deliberations with our international Scientific Advisory Board, the decision was taken to fund two application

Professor Louis Chesler will receive a research grant of £469,093, the biggest ever amount awarded by Neuroblastoma UK for one project. Prof Chesler's research aims to develop less painful blood-based biomarker tests for children with high-risk neuroblastoma, to help guide diagnosis and treatment.

Dr Mark Gaze will receive a research grant of £214,385 to develop targeted, non-invasive radiotherapy for children with high-risk neuroblastoma. The team will also look to start a clinical trial to assess the effectiveness of radioactive antibodies in killing cancer cells.

2021 remained a challenging year for all charities although Neuroblastoma UK's decision to not furlough our small team proved pivotal in ensuring a successful outturn. Fundraising generated a 28% improvement compared with 2020 with significant growth in individual giving mainly attributable to increased awareness through our communications programme. Due to the effects of Covid, events and challenges were heavily impacted most notably the London Marathon although we expect this to return to more normal levels in 2022.

We broadened our base of Patron's with Angellica Bell (TV and Radio presenter) and Scott Mills (Radio One and Five Live Radio Presenter) joining to work alongside our existing Patron Alan Carr. Alan continues to support the charity through fundraising and increased media activity including ITV's This Morning show where he discussed Children's Cancer Awareness Month with emphasis

on Neuroblastoma. We had to postpone the filming of our marketing and promotional videos due to covid but plans are in place to complete in 2022.

We had hoped to hold our Neuroblastoma symposium in 2021 but again covid conspired against us. Due to the number of global and National meetings that have been postponed over the last two years, the calendar has become very congested for 2022 so it is unlikely that our symposium will be able to be held until 2023

Section E Financial Review

Reserves Policy

The annual income generated by the Charity is to be applied for charitable purposes in accordance with the Trust's objective. Year on year the trustees intend to make a full distribution of available income, subject to making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research, but not immediately required are invested in line with the investment policy described below. The balance held as unrestricted reserves at 31 December, 2021 was £637,454 (2019 £326,814).

Investment Policy

The Trustees' intention is to maintain funds so that they are readily accessible when required, but are earning a reasonable return whilst not utilised. Trustees reviewed this policy in February 2005 and confirmed their policy of only placing funds in investments where the book value of the principal is maintained.

Statement of Trustees Responsibilities

The trustees are responsible for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity Law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with the United Kingdom Generally Accepted Accounting Practice (United Kingdom Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for that period. In preparing those financial statements the trustees are required to:

- ☐ select suitable accounting policies and then apply them consistently;
- ☐ observe the methods and principles in the Charities SORP (FRS102)
- ☐ make judgements and estimates that are reasonable and prudent;
- ☐ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- ☐ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding

the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Trustees at a Zoom meeting on 21 July, 2022

Signed on their behalf and with their approval by:

MR T HEDDON
Chair

MR M DEAN
Trustee and Treasurer

Independent Examiner's Report to the Trustees of Neuroblastoma UK

I report to the trustees on the examination of the accounts of Neuroblastoma UK for the year ended 31 December, 2021.

Respective responsibilities of Trustees and Examiner

The charity's trustees are responsible for the preparation of accounts in accordance with the requirements of the Charities Act 2011.

I have reported in respect of the examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out the examination have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

The Charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW.

I have completed the examination and can confirm that no material matters have come to my attention in connection with the examination, which gives me reasonable cause to believe that in, any material respect:

- ☐ the accounting records were not kept in accordance with section 130 of the Charities Act
- ☐ the accounts did not accord with the accounting records; or
- ☐ the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mr. Michael Forshaw FCA
Haines Watts
Pacific Chambers
11-13 Victoria Street
Liverpool
L2 5QQ

NEUROBLASTOMA UK

STATEMENT OF FINANCIAL ACTIVITIES

YEAR ENDED 31 DECEMBER, 2021

Funds	Note	Unrestricted Funds		Unrestricted	
		31 December, 2021		31 December,	
2020		£	£	£	£
INCOME AND ENDOWMENTS FROM:					
Donations	2		387,955		311,486
Other trading activities	3		29,238		23,907
Income from investments	4		130		5,515
TOTAL			417,323		340,908
EXPENDITURE ON:					
Raising funds	5	(7,996)		(3,758)	
Charitable activities:					
Grants payable and grant amendments	6	(9,333)		(329,390)	
Governance costs	7	(104,354)		(107,668)	
TOTAL			(121,683)		(440,816)
NET (EXPENDITURE)/INCOME			295,640		(99,908)
RECONCILIATION OF FUNDS					
Total funds brought forward			326,914		426,822
TOTAL FUNDS CARRIED FORWARD			622,554		326,914

NEUROBLASTOMA UK

BALANCE SHEET

AS AT 31 DECEMBER, 2021

	Note	2021 £	2020 £
CURRENT ASSETS			
Debtors and advance payments	9	20,515	11,753
Investments	10	959,763	959,691
Cash at bank	11	362,384	369,149
TOTAL CURRENT ASSETS		1,342,662	1,340,593
CREDITORS: Amounts falling due due within one year	12	(480,230)	(563,209)
NET CURRENT ASSETS		862,432	777,385
CREDITORS: Amounts falling due in more than one year	13,14	(239,877)	(450,471)
NET ASSETS		622,554	326,914
FUNDS OF THE CHARITY			
Unrestricted fund	15	622,554	326,914

The financial statements set out on pages 8 – 13 were approved by the Trustees on

TRUSTEE - Mr T Heddon

TRUSTEE - Mr M Dean

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER, 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable trust, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015)', the Financial Reporting Standard 102 (effective January 2015) and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Donations

Cash donations and gifts are included in full in the Statement of Financial Activities when they are received by the charity. Cash collected at special fund-raising events is included in the income and expenditure account after deducting the expenditure incurred directly in staging the event. Significant non-cash donations are included in the income and expenditure account at the Trustees' estimation of their market value when received.

Income from investments

Investment income is included in the Statement of Financial Activities on an accruals basis.

Research Grant Awards

These are charged to the Statement of Financial Activities when the Trustees have awarded them. Research grants awarded, but not disbursed at the balance sheet date, are carried forward as grant creditors in the balance sheet.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Cash Flow Statements

The Charity has taken advantage of the exemption provided by the Charities SORP (FRS102) and does not prepare a cash flow statement.

Taxation

The charity is exempt from Taxation on its charitable activities.

VAT

As a non-trading organisation the charity is not registered for VAT purposes, and is unable to recover VAT incurred on its expenditure.

NEUROBLASTOMA UK
NOTES TO THE ACCOUNTS (Continued)
YEAR ENDED 31 DECEMBER, 2021

2.	DONATIONS	2021	2020
		£	£
	Donations and fund-raising	387,955	311,486
3.	OTHER TRADING ACTIVITIES	2021	2020
		£	£
	Job Retention Scheme grant	750	
	Christmas cards, webshop and other income	28,488	23,907
		29,238	
			23,907
4.	INCOME FROM INVESTMENTS	2021	2020
		£	£
	COIF deposit	72	1,599
	National savings income bonds	58	3,916
		130	5,515
5.	EXPENDITURE ON RAISING FUNDS	2021	2020
		£	£
	Fund-raising and publicity costs	7,996	3,758
6.	GRANTS PAYABLE AND GRANT AMENDMENTS	2021	2020
		£	£
		4,98	
	University of Birmingham	1	175,000
	Straathof		154,492
	Ramanujachar		5,517
		9,33	
	Conferences, Travel and Other Grants	3	
	Write back	(4,981)	(5,619)
		9,333	

7. EXPENDITURE ON CHARITABLE ACTIVITIES

	2021 £	2020 £
Rent and facilities	11,163	16,217
Staff salaries and pension contributions	66,767	61,203
Staff training	435	Nil
Sporting event costs	902	3,024
Subscriptions	1,622	1,146
Travel	78	77
Computers, software and equipment hire	2,905	1,035
Accounts and audit	10,872	10,604
Trustees meeting costs	Nil	452
Printing, postage and stationery	604	1,526
Sundries	804	1,596
Advertising and website	6,633	4,656
Insurance	977	955
Bank and professional charges	592	5,167
Seminar costs	Nil	10
	104,354	107,668

8. TRUSTEES' REMUNERATION AND BENEFITS

There was no trustees' remuneration or other benefits for the year ended 31 December, 2021

(2020 £NIL).

The Trust owns no premises.

9. DEBTORS AND PREPAYMENTS

	2021 £	2020 £
Receivables	1,188	3,495
Prepayments	6,827	8,257
Co-funding income	12,500	
	20,515	11,753

10. CURRENT INVESTMENTS

	2021 £	2020 £
COIF Deposit Fund	609,763	609,691

National Savings – Income bonds	350,000	350,000
	959,763	959,691

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS (Continued)

YEAR ENDED 31 DECEMBER, 2021

11. CASH AT BANK AND IN HAND

	2021	2020
	£	£
Cash at Bank	<u>362,384</u>	<u>369,149</u>

12. CREDITORS - DUE WITHIN ONE YEAR

	2021	2020
	£	£
Grant commitments	442,311	551,133
Trade creditors	22,019	11,176
Accruals	900	900
Co-funding income received in advance	<u>15,000</u>	
	<u>480,230</u>	<u>563,209</u>

13. CREDITORS - DUE IN MORE THAN ONE YEAR

	2021	2020
	£	£
Grant commitments	<u>239,877</u>	<u>450,471</u>

14. GRANT COMMITMENTS

	2021	2020
	£	£
Total commitments at 1 January, 2021	1,001,604	774,342
Paid in the year	(319,415)	(102,128)
New commitments	4,981	335,009
Written back in the year	<u>(4,981)</u>	<u>(5,619)</u>
	<u>682,189</u>	<u>1,001,609</u>

All of the grants paid in 2021 and 2020 were to institutions and to commission research studies.

All of the new grant commitments in 2021 were to institutions.

15. ANALYSIS OF UNRESTRICTED FUND

2021 2020

	£	£
At 1 January, 2021	326,914	426,822
Net movement in funds for the year	295,640	(99.908)
	622,554	326,914

Accounts



NEUROBLASTOMA UK

Charity Commission reference number
326385

REPORTS AND FINANCIAL STATEMENTS

For the year ended 31 December, 2020

NEUROBLASTOMA UK

REPORT AND FINANCIAL STATEMENTS

For the year ended 31 December, 2020

CONTENTS

	Page
Trustees' annual report	3-5
Independent Examiner's Report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9-13

TRUSTEES' ANNUAL REPORT for the year to 31 December, 2020

The Trustees present their report with the financial statements of the charity for the year ended 31 December, 2020. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015). As a charity registered in England and Wales, the charity also reports in accordance with the Charity Commission for England and Wales' guidance on public benefit and the Charities Act 2015.

Section A Reference and administrative details

Charity Name NEUROBLASTOMA UK
Registered Charity Number 326385
Registered Address 7/14 Great Dover Street, London SE1 4YR

Trustees who manage the charity:

Tony Heddton (Chair)
Shirley Clark (Secretary) – retired 14 December, 2020
Carolyn Jackson (Secretary) – appointed 9 June, 2020
Malcolm Dean (Treasurer)
Zara Aitchison
Guy Blanchard – retired 9 June, 2020
Ruby Dickens
Faith Gibson – retired 9 June, 2020
Keith Holmes
Jane Morris
Monica Proctor
Stephen Smith
Faye Watts
Alastair Whittington
Debbie Tweddle
Kate Wheeler

Independent Examiner Haines Watts, Statutory Auditor, 3rd Floor Pacific Chambers, 11-13 Victoria Street, Liverpool, L2 5QQ

Bankers Barclays Bank PLC, Newmarket, LE87 2BB

Public Benefit Requirement

The trustees of Neuroblastoma UK confirm that they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties.

Section B Structure, governance and management

Governing Document

The Trust is an unincorporated trust, constituted under a Trust Deed dated 20 May, 1983 and is a registered Charity number 326385.

Recruitment and appointment of new trustees

Lay Trustees are appointed by the Trustees following consideration of applications received from individuals. Medical Trustees are appointed by the Trustee on the recommendation of existing Medical Trustees.

Risk Management

Trustees have considered the major risks to which the charity may be exposed; have reviewed them and established systems and procedures to manage them. Trustees consider the possibility that money placed on investment could be at risk if the organisation holding the deposit should fail. Although current investments are

placed with large, well-established financial institutions Trustees identified the need to re-examine investment policy and have concluded that investments should be spread across a number of institutions to minimise the impact if a single fund-holder should fail. The Trust is essentially a cash based charity, holding no property. The Charity has developed sufficient internal controls to monitor and minimise the risk of misappropriation of funds.

Section C Objectives and activities

Objectives and aims

The object of the Charity is to provide relief for children suffering from Neuroblastoma, and to achieve this, it raises funds for medical research into improving both diagnosis and treatment of the disease. The Charity also offers an opportunity for parents to give each other mutual help, support and comfort.

Policy on Grant-making

Trustees invite applications for grant award by public advertisement, typically on the Charity's website. Normally this is biennially so that sufficient funds are available to commission meaningful research studies, although exceptions are occasionally made when judged appropriate by the Trustees in consultation with the Charity's Scientific Advisory Board (SAB). Applications are first considered by the Charity's SAB, which is made up of 5 scientists experienced in Neuroblastoma research and a chairman who is a paediatric oncology clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist knowledge of the research area proposed, and by a response from the applicants to those reports. The SAB then recommends to Trustees applications worthy of grant funding in order of merit. Trustees award grants in the light of the SAB's advice and funds available. Grants are only awarded to the extent that resources have already accrued in the Charity's unrestricted fund or appropriate restricted fund.

Section D Achievements and performance

Charitable activities

As with many charities, 2020 proved challenging. The Covid crisis and the need for extended periods of lockdown had a significant affect on our ability to raise funds through social and sporting events. Most notably the London Marathon our key fundraiser. We took the decision not to furlough our colleagues which enabled us to continue developing awareness and providing support to our fundraisers in a way which we would not have been able to do had they not been actively engaged. This decision enabled us to exit the year with only a small reduction in year-on-year donations, the majority of which were one-off legacy donations with the day-to-day run rate remaining solid.

Our Patron, Alan Carr, proved a vital outlet for funding, holding virtual on-line quizzes during lockdown and a in-person appearance a week before the first lockdown. We also benefited from his media and television appearances. He has agreed to front a new awareness and fundraising campaign in late summer generating a new suite of marketing and media materials.

The One Sock Story campaign in late 2020 not only raised valuable funds but also introduced us to Radio One DJ, Scott Mills, who has subsequently agreed to join Alan as a patron. These celebrity endorsements, along with the continued efforts of our team, have seen significant increase in traffic through our social media channels and our website.

The reduced level of funding and the number of researchers on furlough, forced us to delay our bi-annual research grant round until mid 2021. This will enable us to increase available funds for the round and allow for a higher number of applications.

Our most significant new investment was the funding of the HR2 Trial for the Neuroblastoma community ensuring that all children will have access to the latest clinical trials from across Europe for the next 10 years

We are planning to hold our 6th Neuroblastoma Research Symposium towards the end of 2021 or beginning of 2022 dependent upon the developments with covid

Section E Financial Review

Reserves Policy

The annual income generated by the Charity is to be applied for charitable purposes in accordance with the Trust's objective. Year on year the trustees intend to make a full distribution of available income, subject to making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research, but not immediately required are invested in line with the investment policy described below. The balance held as unrestricted reserves at 31 December, 2020 was £326,914 (2019 £426,822).

Investment Policy

The Trustees' intention is to maintain funds so that they are readily accessible when required, but are earning a reasonable return whilst not utilised. Trustees reviewed this policy in February 2005 and confirmed their policy of only placing funds in investments where the book value of the principal is maintained.

Statement of Trustees Responsibilities

The trustees are responsible for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity Law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with the United Kingdom Generally Accepted Accounting Practice (United Kingdom Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for that period. In preparing those financial statements the trustees are required to:

- ❖ select suitable accounting policies and then apply them consistently;
- ❖ observe the methods and principles in the Charities SORP (FRS102)
- ❖ make judgements and estimates that are reasonable and prudent;
- ❖ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- ❖ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Trustees on

Signed on their behalf and with their approval by:

MR T HEDDON
Chair

MR M DEAN
Trustee and Treasurer

Independent Examiner's Report to the Trustees of Neuroblastoma UK

I report to the trustees on the examination of the accounts of Neuroblastoma UK for the year ended 31 December, 2020.

Respective responsibilities of Trustees and Examiner

The charity's trustees are responsible for the preparation of accounts in accordance with the requirements of the Charities Act 2011.

I have reported in respect of the examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out the examination have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

The Charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW.

I have completed the examination and can confirm that no material matters have come to my attention in connection with the examination, which gives me reasonable cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mr. Michael Forshaw FCA
Independent Examiner
Haines Watts
Pacific Chambers
11-13 Victoria Street
Liverpool
L2 5QQ

NEUROBLASTOMA UK

STATEMENT OF FINANCIAL ACTIVITIES

YEAR ENDED 31 DECEMBER, 2020

	Note	Unrestricted Funds 31 December, 2020 £	Unrestricted Funds 31 December, 2019 £
INCOME AND ENDOWMENTS FROM:			
Donations	2	311,486	262,859
Other trading activities	3	23,907	124,811
Income from investments	4	5,515	6,936
TOTAL		340,908	394,606
EXPENDITURE ON:			
Raising funds	5	(3,758)	(2,985)
Charitable activities:			
Grants payable and grant amendments	6	(329,390)	(716,305)
Governance costs	7	(107,668)	(81,434)
TOTAL		(440,816)	(800,724)
NET (EXPENDITURE)/INCOME		(99,908)	(406,118)
RECONCILIATION OF FUNDS			
Total funds brought forward		426,822	832,940
TOTAL FUNDS CARRIED FORWARD		326,914	426,822

NEUROBLASTOMA UK

BALANCE SHEET

AS AT 31 DECEMBER, 2020

	Note	2020 £	2019 £
CURRENT ASSETS			
Debtors and advance payments	9	11,753	16,212
Investments	10	959,691	958,092
Cash at bank	11	369,150	242,177
TOTAL CURRENT ASSETS		1,340,594	1,216,481
CREDITORS: Amounts falling due within one year	12	(563,209)	(431,063)
NET CURRENT ASSETS		777,385	785,418
CREDITORS: Amounts falling due in more than one year	13,14	(450,471)	(358,596)
NET ASSETS		326,914	426,822
FUNDS OF THE CHARITY			
Unrestricted fund	15	326,914	426,822

The financial statements set out on pages 8 – 13 were approved by the Trustees on

TRUSTEE – Mr T Heddon

TRUSTEE – Mr M Dean

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS

YEAR ENDED 31 DECEMBER, 2020

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable trust, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015)', the Financial Reporting Standard 102 (effective January 2015) and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Donations

Cash donations and gifts are included in full in the Statement of Financial Activities when they are received by the charity. Cash collected at special fund-raising events is included in the income and expenditure account after deducting the expenditure incurred directly in staging the event. Significant non-cash donations are included in the income and expenditure account at the Trustees' estimation of their market value when received.

Income from investments

Investment income is included in the Statement of Financial Activities on an accruals basis.

Research Grant Awards

These are charged to the Statement of Financial Activities when the Trustees have awarded them. Research grants awarded, but not disbursed at the balance sheet date, are carried forward as grant creditors in the balance sheet.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Cash Flow Statements

The Charity has taken advantage of the exemption provided by the Charities SORP (FRS102) and does not prepare a cash flow statement.

Taxation

The charity is exempt from Taxation on its charitable activities.

VAT

As a non-trading organisation the charity is not registered for VAT purposes, and is unable to recover VAT incurred on its expenditure.

NEUROBLASTOMA UK
NOTES TO THE ACCOUNTS (Continued)
YEAR ENDED 31 DECEMBER, 2020

2. DONATIONS

	2020	2019
	£	£
Donations and fund-raising	311,486	248,474
Collecting Boxes		1,236
Regular Giving		6,192
Gift Aid Tax Recoverable		6,957
	311,486	262,859

3. OTHER TRADING ACTIVITIES

	2020	2019
	£	£
Sponsorship from marathons and sporting events		3,750
Co-funding – Smile with Siddy Chesler		86,771
Christmas cards, webshop and other income	23,907	34,290
	23,907	124,811

4. INCOME FROM INVESTMENTS

	2020	2019
	£	£
COIF deposit	1,599	2,911
National savings income bonds	3,916	4,025
	5,515	6,936

5. EXPENDITURE ON RAISING FUNDS

	2020	2019
	£	£
Fund-raising and publicity costs	3,758	2,985

6. GRANTS PAYABLE AND GRANT AMENDMENTS

	2020 £	2019 £
Turner		236,141
Laman (net of co-funding income)		3,369
Stoker		143,648
Chesler		205,238
Tsakiridis		36,328
Piskareva		116,400
Grey (net of co-funding income)		1,990
Walters		5,000
Guo/Falconer		4,950
University of Birmingham	175,000	
Straathof	154,492	
Ramanujachar	5,517	
Conferences, Travel and Other Grants		
Write back	(5,619)	(36,759)
	329,390	716,305

7. EXPENDITURE ON CHARITABLE ACTIVITIES

	2020 £	2019 £
Rent and facilities	16,217	14,399
Establishment costs		987
Staff salaries and pension contributions	61,203	30,145
Staff training		579
Sporting event costs	3,024	2,200
Subscriptions	1,146	6,734
Travel	77	797
Computers, software and equipment hire	1,035	1,056
Accounts and audit	10,604	10,944
Trustees meeting costs	452	860
Printing, postage and stationery	1,526	1,757
Sundries	1,596	351
Advertising and website	4,656	5,736
Insurance	955	906
Bank and professional charges	5,167	122
Seminar costs	10	3,861
	107,668	81,434

8. TRUSTEES' REMUNERATION AND BENEFITS

There was no trustees' remuneration or other benefits for the year ended 31 December, 2020 (2019 £NIL).

The Trust owns no premises.

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS (Continued)

YEAR ENDED 31 DECEMBER, 2020

9. DEBTORS AND PREPAYMENTS

	2020	2019
	£	£
Gift Aid Tax Recoverable		6,957
Receivables	3,496	2,230
Prepayments	8,257	7,025
	11,753	16,212

10. CURRENT INVESTMENTS

	2020	2019
	£	£
COIF Deposit Fund	609,691	608,092
National Savings – Income bonds	350,000	350,000
	959,691	958,092

11. CASH AT BANK AND IN HAND

	2020	2019
	£	£
Cash at Bank	369,209	242,177

12. CREDITORS – DUE WITHIN ONE YEAR

	2020	2019
	£	£
Grant commitments	551,133	415,746
Trade creditors	11,176	14,317
Accruals	900	1,000
	563,209	541,063

13. CREDITORS – DUE IN MORE THAN ONE YEAR

	2020	2019
	£	£
Grant commitments	450,471	358,596

NEUROBLASTOMA UK

NOTES TO THE ACCOUNTS (Continued)

YEAR ENDED 31 DECEMBER, 2020

14. GRANT COMMITMENTS

	2020	2019
	£	£
Total commitments at 1 January, 2020	774,342	282,736
Paid in the year	(102,128)	(224,700)
New commitments	335,009	753,064
Written back in the year	(5,619)	(36,759)
	1,001,604	774,342

All of the grants paid in 2020 and 2019 were to institutions and to commission research studies.

All of the new grant commitments in 2020 were to institutions.

15. ANALYSIS OF UNRESTRICTED FUND

	2020	2019
	£	£
At 1 January, 2020	426,822	832,940
Net movement in funds for the year	(99,908)	(406,118)
	326,914	426,822